Core Viewpoint - Changsen Pharmaceutical has completed a multi-hundred million RMB B+ round financing, led by Qiming Venture Partners, aimed at advancing key clinical research and global expansion [1] Company Overview - Changsen Pharmaceutical was founded in 2012 by renowned chemical drug research expert Wang Zhe, focusing on innovative drug development and commercialization in the fields of antiviral immunity, autoimmune diseases, and tumor immunotherapy [1] - The company has multiple indications entering clinical phases II and III, with core product clinical data reaching international leading levels [1] Product Highlights - The dual-functional, dual-target hepatitis B cure drug LW231 and the new generation autoimmune disease drug LW402 are expected to significantly meet clinical needs in their respective fields and may represent major breakthrough achievements [1]